# BridgeBio Pharma share price today (BridgeBio Pharma, Inc., BBIO)

> BridgeBio Pharma, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. BBIO · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/bbio

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $74.27 (+20.2% in a year)
- Revenue (Jun 2026): $244 M (+120.4% on a year ago)
- Profit (Jun 2026): −$152 M
- Operating margin: −43.9% (+76.8 points on a year ago)
- ROE: 35%, FY25
- ROIC: −17.7%, against a 8.6% cost of capital: −26.3 points

Biggest thing to watch: the price has already been rising for 2 weeks, so timing is the risk more than the business. ## What is the BridgeBio Pharma share price today? BridgeBio Pharma, Inc.'s share price was $74.27 at the close on 5 November 2026. It has been rising for 2 weeks. That is 2.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $62 and $86, and at that close it sat 52% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running. Over the last 7.4 years the share price moved +175% while the S&P 500 moved +150%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does BridgeBio Pharma pay? BridgeBio Pharma, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is BridgeBio Pharma on? BridgeBio Pharma is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is BridgeBio Pharma profitable? BridgeBio Pharma, Inc. posted a net loss of $152 M in the Jun 2026 quarter. The full FY25 year was a loss of $725 M. That loss is 62.5% of the quarter's revenue. The same quarter a year earlier lost $182 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does BridgeBio Pharma make, and is it growing? BridgeBio Pharma, Inc. reported $244 M of revenue in the Jun 2026 quarter, +120.4% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown 63.8% a year on average. The last full year, FY25, came in at $502 M. The last four reported quarters add to $713 M. FY25 revenue was $502 M, +126.3% on the year before. Recent pace: the last four quarters grew +1,756.6% on average, against 63.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +202.4%, against +80.4% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does BridgeBio Pharma keep? BridgeBio Pharma, Inc.'s operating margin was −43.9% in the Jun 2026 quarter, 76.8 percentage points higher than the same quarter a year ago. Across 5 years it has been between −6,443.6% and −100.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +76.8 percentage points on the year while gross margin changed −2.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is BridgeBio Pharma's profit turning into cash? BridgeBio Pharma, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $446 M of cash, against −$725 M of profit. After $1.1 M of spending on assets, free cash was −$447 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does BridgeBio Pharma's cash go? BridgeBio Pharma, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.3 M on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $3.3 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is BridgeBio Pharma's P/E ratio, and how does it compare with its own history? BridgeBio Pharma, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values BridgeBio Pharma, Inc. at 28.8× its FY25 revenue of $502 M. The P/E comes back here once profit turns positive. ## Is the BridgeBio Pharma business getting better or worse? BridgeBio Pharma, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does BridgeBio Pharma earn on its capital? BridgeBio Pharma, Inc. earned a ROE of 35% in FY25. Its return on capital used (ROIC) is 26.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −144.4% net margin and 0.54× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −144.4% net margin × 0.54× asset turnover × −0.45× leverage (assets divided by equity) ≈ 35.1% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −17.7% − 8.6% = −26.3 percentage points. The 8.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does BridgeBio Pharma have too much debt? BridgeBio Pharma, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −1.99 in FY21 to −0.90 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the BridgeBio Pharma shareholding pattern? 12.0% of BridgeBio Pharma, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is BridgeBio Pharma from balance-sheet trouble? For BridgeBio Pharma, Inc., the Z-score is −0.04. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.04 is inside the danger zone, so the balance sheet is a real risk. ## How does BridgeBio Pharma rank in its industry? 35.2 out of 100, rank 23 of 30 in Biotechnology, with 61% of the evidence available. BridgeBio Pharma, Inc. scores 35.2 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 23. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 17.2 + 3.8 + 10 + 4.2 = 35.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is BridgeBio Pharma compared with? BridgeBio Pharma ranks 23 of 30 Biotechnology companies on the 4-Factor Sector Score, with 35.2 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.6/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.9/20 · Lead over its industry 9.7% · Lead over S&P 500 35.4% · 1 year 68.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.7 + 20.9 + 14.6 + 17.9 = 76.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) HALO · leader · Most evidence points up · 81% evidence 72.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 20.9/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.6/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.8/20 · Lead over its industry 21.7% · Lead over S&P 500 48.8% · 1 year 80.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.7 + 20.9 + 14.6 + 18.8 = 72 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Most evidence points up · 71% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.5/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.9/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 7.2/20 · Lead over its industry -12.7% · Lead over S&P 500 8.2% · 1 year 11.4% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.1 + 20.5 + 10.9 + 7.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.0/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.6/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 15.1/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 33.6% · Lead over S&P 500 65.2% · 1 year 83.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11 + 15.6 + 15.1 + 19.5 = 61.2 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 5. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) ARGX · turning · Evidence leans up · 85% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 17.1/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 10.4/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 8.4/20 · Lead over its industry -17.4% · Lead over S&P 500 2.7% · 1 year 4.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.9 + 17.1 + 10.4 + 8.4 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.3/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry -6.3% · Lead over S&P 500 16.5% · 1 year 21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 13.3 + 9.1 + 12.2 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 16.9/20 · Lead over its industry 11% · Lead over S&P 500 36.2% · 1 year 118.4% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.9 + 6.8 + 10 + 16.9 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 11.0/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 21.2% · Lead over S&P 500 46.6% · 1 year 328.9% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.6 + 8.6 + 11 + 12.9 = 56.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue -27.6% · Profit n/a · Operating margin change 80.8 points · 62% evidence Capital efficiency 6.5/25 · ROCE -28.9% · Operating margin -557.9% · 76% evidence Valuation 11.2/20 · P/E -11.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 161.6% · Lead over S&P 500 205.6% · 1 year 882.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 6.5 + 11.2 + 20 = 55.1 · What this means: Relative strength against the index is 205.6%, and revenue and profit growth are weak. 10. [Krystal Biotech, Inc.](https://www.sectoralpha.in/us/stocks/krys) KRYS · quiet · Evidence leans up · 81% evidence 55.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 22.6% · Profit 65.1% · Operating margin change 8 points · 83% evidence Capital efficiency 16.1/25 · ROCE 14.4% · Operating margin 49% · 76% evidence Valuation 12.4/20 · P/E 45.4× · PEG 0.77 · 65% evidence Relative strength 4.1/20 · Lead over its industry -19% · Lead over S&P 500 0.1% · 1 year 51.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 22.4 + 16.1 + 12.4 + 4.1 = 55 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 55.0 out of 100 Growth Capital Valuation Relative
12. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 53.7 out of 100 Growth Capital Valuation Relative
13. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) REGN · leader · Evidence leans up · 81% evidence 52.8 out of 100 Growth Capital Valuation Relative
14. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) ALNY · basing · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative
15. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.6 out of 100 Growth Capital Valuation Relative
16. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans down · 85% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 44.4 out of 100 Growth Capital Valuation Relative
18. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 39.5 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.2 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 38.7 out of 100 Growth Capital Valuation Relative
21. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 37.2 out of 100 Growth Capital Valuation Relative
22. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
23. BridgeBio Pharma, Inc. this page BBIO · quiet · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.2/35 · Revenue 100% · Profit n/a · Operating margin change 76.8 points · 62% evidence Capital efficiency 3.8/25 · ROCE -146.3% · Operating margin -43.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 4.2/20 · Lead over its industry -19.8% · Lead over S&P 500 0.1% · 1 year 20.2% · 100% evidence · 4 of 12 weeks ahead Exact sum: 17.2 + 3.8 + 10 + 4.2 = 35.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 24. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) BNTX · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.8 out of 100 Growth Capital Valuation Relative
26. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.3 out of 100 Growth Capital Valuation Relative
27. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 47.2 out of 100 Growth Capital Valuation Relative
28. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 41.2 out of 100 Growth Capital Valuation Relative
29. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) CRNX · Too little evidence to rank firmly · 35% evidence 38.0 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 37.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to BridgeBio Pharma in size? BridgeBio Pharma is the 17th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Exelixis, Inc., Ascendis Pharma A/S and Jazz Pharmaceuticals plc. Just below it: Halozyme Therapeutics, Inc., Bio-Techne Corporation and Summit Therapeutics Inc. ### Biotechnology companies close in size

1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) $16.8 billion
2. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) $16.6 billion
3. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) $14.6 billion
4. BridgeBio Pharma, Inc. $14.5 billion
5. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) $14 billion
6. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) $11.4 billion
7. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) $11.3 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) $15.2 billion · Medical Instruments & Supplies
2. [Clean Harbors, Inc.](https://www.sectoralpha.in/us/stocks/clh) $15.2 billion · Waste Management
3. BridgeBio Pharma, Inc. $15.2 billion
4. [Fair Isaac Corporation](https://www.sectoralpha.in/us/stocks/fico) $15.1 billion · Software - Application
5. [APA Corporation](https://www.sectoralpha.in/us/stocks/apa) $15.1 billion · Oil & Gas Exploration & Production

## What else do people ask about BridgeBio Pharma? ### What were BridgeBio Pharma's latest quarterly results? BridgeBio Pharma, Inc. reported revenue of $244 M and a net loss of $152 M for the Jun 2026 quarter. Earnings per share were −$0.78. The operating margin was −43.9%, 76.8 percentage points higher than a year earlier (as of 5 November 2026). ### What is BridgeBio Pharma's market cap? BridgeBio Pharma, Inc.'s market capitalisation is $14.5 B at a stock price of $74.27. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is BridgeBio Pharma performing? BridgeBio Pharma, Inc.'s share price has been rising for 2 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 8 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will BridgeBio Pharma's stock price go up? This page does not forecast BridgeBio Pharma, Inc.'s stock price. What it shows instead: the stock price is $74.27, and it has been rising for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is BridgeBio Pharma in its business cycle? BridgeBio Pharma, Inc.'s FY25 operating margin was −100.0%, against a 5-year range of −6,443.6% to −100.0%: the middle of its own range, neither a peak nor a low. The latest quarter was −43.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the BridgeBio Pharma story? Biggest thing to watch: the price has already been rising for 2 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is BridgeBio Pharma a stock worth studying right now? What the numbers show: BridgeBio Pharma, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.